Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 5, 2015, Pages 769-772

  Arbyn, Marc ^a   Castle, Philip E ^b,c  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Global Coalition Against Cervical Cancer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; GENERAL DEVICE; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MOLECULAR DIAGNOSTICS; PHYSICIAN; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

EID: 84938590267     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1417     Document Type: Article

References (20)

1. Rozemeijer K, de Kok IMCM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, et al. Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev 2015;24:773-82.
2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012;30 Suppl 5: F88-F99.
3. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383:524-32.
4. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and metaanalysis. Can J Public Health 2013;104:e159-66.
5. RIVM [Rijksinstituut voor Volksgezondheid en Milieu (National Institute of Public Health and the Environment)]. Population screening for cervical cancer will change (in Dutch). Bilthoven, the Netherlands: 2014.
6. Schippers EI. Improvement of the cervical cancer screening program (in Dutch). [Letter of the Ministry of Welfare, Public Health and Sport, 17 Oct 2013 (156231-111126-PG)]. 2013.
7. Bos AB, Rebolj M, Habbema JDF, van Ballegooijen M. Non attendance is still themain limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006;119:100-4.
8. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening-a randomised controlled trial. Br J Cancer 2011;104: 915-20.
9. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:1505-10.
10. Giorgi-Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011;104:248-54.
11. Broberg G, Gyrd-Hansen D, Jonasson JM, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer 2014;134:2223-30.
12. Arbyn M, Verdoodt F, Snijders PJF, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15: 172-83.
13. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de Ridder GM, et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int J Cancer 2015;136:646-55.
14. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer 2013; 23:513-8.
15. Zhao FH, Jeronimo JA, Qiao YL, Schweizer J, Chen W, Valdez M, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in Rural China. Cancer Prev Res 2013;6:938-48.
16. Hesselink A, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, et al. Clinical validation of the HPV-risk assay: a novel, realtime PCR assay for the detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol 2014;52:890-6.
17. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening non-attenders from lower socio-economic groups in France. Int J Cancer 2013;133:2681-7.
18. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011;20:1960-9.
19. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12:880-90.
20. Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, et al. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol 2014;135:58-63.